Young Shin Cho

USPTO Granted Patents = 10 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 9.4

ph-index = 5

Forward Citations = 44(Granted Patents)

Company Filing History:

Astex Therapeutics Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10112931 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2018-10-30),

2. 9688672 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2017-06-27),

3. 9434719 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2016-09-06),

4. 9309252 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2016-04-12),

5. 8957074 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2015-02-17),

6. 8957068 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2015-02-17),

7. 8598217 - Imidazole derivatives and their use as modulators of cyclin dependent kinases (2013-12-03),

8. 8367687 - Pyrazole derivatives (2013-02-05),

9. 8349883 - Hydroxamate-based inhibitors of deacetylases B (2013-01-08),

10. 7943652 - Hydroxamate-based inhibitors of deacetylases B (2011-05-17),

Title: Young Shin Cho: Innovator in Pharmaceutical Chemistry

Introduction

Young Shin Cho is a prominent inventor based in Cambridge, MA, known for his significant contributions to pharmaceutical chemistry. With a total of 10 patents to his name, he has made remarkable strides in the field of drug development, particularly in the treatment of diseases associated with mutant IDH proteins.

Latest Patents

Among his latest innovations are the patents for 3-pyrimidin-4-yl-oxazolidin-2-ones, which serve as inhibitors of mutant IDH. These inventions are directed to a specific formula, or a pharmaceutically acceptable salt thereof, wherein various substituents are defined. The patents also encompass compositions containing this compound and its application in inhibiting mutant IDH proteins that exhibit neomorphic activity. Furthermore, these compounds are intended for use in treating diseases or disorders linked to such mutant IDH proteins, including cell-proliferation disorders like cancer.

Career Highlights

Throughout his career, Young Shin Cho has worked with notable companies such as Novartis AG and Astex Therapeutics Limited. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Young Shin Cho has collaborated with esteemed colleagues, including Julian Roy Levell and Gang Liu, who have contributed to his research endeavors.

Conclusion

Young Shin Cho's innovative work in pharmaceutical chemistry, particularly in the development of inhibitors for mutant IDH proteins, showcases his dedication to advancing medical science. His contributions continue to have a significant impact on the treatment of serious diseases.

This text is generated by artificial intelligence and may not be accurate.